Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MEDICAL PRODUCT/PROVIDER LIABILITY BILL WILL BE INTRODUCED IN "NEXT FEW WEEKS"

Executive Summary

A medical liability bill that includes both products and providers under its umbrella is expected to be introduced "in the next few weeks," Sen. McCain (R-Ariz.) told the Pharmaceutical Manufacturers Association annual meeting April 30. "Several months ago it occurred to me and others that someone ought to start looking at the possibility of addressing both provider and products liability in a single bill," McCain said. The Arizona Republican said he believes that the "liability crisis is facing the whole health care system [and consequently] not just providers should be addressed." He noted that he has been working on the proposal with Sens. Danforth (R-Mo.) and Durenberger (R- Minn.). The proposal "incorporates the ideas of many members [of Congress] who have been active in this area, including Sen. Hatch [R-Utah]," McCain reported. "Increasingly," he contended, "products are not coming to market due to the crisis. If they ultimately do become available, they are much delayed and much costlier." The Arizona Republican's legislation would establish uniform standards for medical liability cases; cap non-economic damages at $ 350,000; limit attorneys' fees to 25% on the first $ 150,000 of damages and 15% on the balance above $ 150,000; provide additional protection to OB/GYNs; establish uniform disciplinary reforms, including strengthening the role of state licensing and peer review boards; assist community health centers in forming risk- retention pools; and provide special protection from large damage awards to medical product and device manufacturers who go through the federal premarket approval process. McCain said he is still "working out just what the specific tort reforms would mean for products." He predicted that the legislation will likely have a tough road ahead. "As you can well appreciate," he told the drug manufacturers group, "if we actually introduce this proposal, we are likely to have a major war on our hands with respect to at least one group that is economically dependent on this system," trial lawyers. The Arizona Republican, who was assigned to the Senate Special Committee on Aging in February, was making his first appearance at a PMA annual meeting. He had not drafted his product/provider liability legislation as of May 3. McCain's health aide, who is working on the measure, is David McIntyre.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS019119

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel